We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.
- Authors
Hui, Tianli; Li, Sainan; Wang, Huimin; Ma, Xuejiao; Du, Furong; Gao, Wei; Yang, Shan; Sang, Meixiang; Li, Ziyi; Ding, Ran; Liu, Yueping; Geng, Cuizhi
- Abstract
Background: In recent years, breast cancer has become the most common cancer in the world, increasing women's health risks. Approximately 60% of breast cancers are categorized as human epidermal growth factor receptor 2 (HER2)-low tumors. Recently, antibody-drug conjugates have been found to have positive anticancer efficacy in patients with HER2-low breast cancer, but more studies are required to comprehend their clinical and molecular characteristics. Methods: In this study, we retrospectively analyzed the data of 165 early breast cancer patients with pT1-2N1M0 who had undergone the RecurIndex testing. To better understand HER2-low tumors, we investigated the RecurIndex genomic profiles, clinicopathologic features, and survival outcomes of breast cancers according to HER2 status. Results: First, there were significantly more hormone receptor (HR)-positive tumors, luminal-type tumors, and low Ki67 levels in the HER2-low than in the HER2-zero. Second, RI-LR (P =.0294) and RI-DR (P =.001) scores for HER2-low and HER2-zero were statistically significant. Third, within HER2-negative disease, HR-positive/HER2-low tumors showed highest ESR1, NFATC2IP, PTI1, ERBB2, and OBSL1 expressions. Fourth, results of the survival analysis showed that lower expression of HER2 was associated with improved relapse-free survival for HR-positive tumors, but not for HR-negative tumors. Conclusions: The present study highlights the unique features of HER2-low tumors in terms of their clinical characteristics as well as their gene expression profiles. HR status may influence the prognosis of patients with HER2-low expression, and patients with HR-positive/HER2-low expression may have a favorable outcome. In this study, the data of patients with early stage breast cancer who had undergone RecurIndex testing was analyzed. To better understand HER2-low tumors, genomic profiles, clinicopathologic features, and survival outcomes of breast cancers according to HER2 status were investigated.
- Subjects
CHINA; BREAST cancer prognosis; THERAPEUTIC use of immunoglobulins; THERAPEUTIC use of antineoplastic agents; EPIDERMAL growth factor receptors; CANCER relapse; RETROSPECTIVE studies; PROTEOMICS; CANCER patients; RISK assessment; GENOMICS; SURVIVAL analysis (Biometry); GENE expression profiling; DESCRIPTIVE statistics; RESEARCH funding; TUMOR markers; BREAST tumors
- Publication
Oncologist, 2023, Vol 28, Issue 12, pe1160
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyad159